AMCP Welcomes Reintroduction of the Medicaid VBPs for Patients Act to Expand Medicaid Access to Novel Therapies

Alexandria, Va., March 11, 2026 ― AMCP (Academy of Managed Care Pharmacy) applauds the House reintroduction of the Medicaid VBPs for Patients (MVP) Act (H.R. 7871) by Rep. Brett Guthrie (KY-02) alongside Rep. Jake Auchincloss (MA-04), Rep. Mariannette Miller-Meeks (IA-01),  Rep. John Joyce (PA-13), Rep. Scott Peters (CA-50), and Rep. Don Davis (NC-01). This bipartisan legislation complements Senate bill S. 1637 and aims to improve patient access to novel therapies by enhancing the use of value-based purchasing arrangements in Medicaid. 

“Passing the MVP Act is one of AMCP’s top federal policy priorities for 2026 and marks an important step toward expanding Medicaid patients’ access to novel therapies,” said Susan Cantrell, MHL, RPh, CAE, CEO of AMCP. “These arrangements can expand patient access to groundbreaking therapies, while protecting states from over-paying for treatments that are not effective. We appreciate the bipartisan leadership behind this legislation and look forward to working with Congress to move it forward.”

The MVP Act will, among other things:  

• Codify federal regulation permitting the reporting of multiple best price points for an outpatient drug;  
• Clarify that the best price under a value-based arrangement is the price paid if all benchmarks are satisfied; and 
• Expand the use of value-based arrangements for drugs administered in an inpatient setting.  

Value-based purchasing arrangements, often called outcomes-based arrangements, enable manufacturers to share risk with payers by tying payments to patient outcomes. Innovative contracts allow payers to recoup some or all of the price of a treatment if it fails, or spread payments over time to reduce budgetary pressure. Value-based payment arrangements are critical tools for ensuring patient access to high-cost treatments, such as cell and gene therapies, which have highly variable outcomes between patients. State Medicaid programs often exclude or restrict coverage due to their high upfront cost under fee-for-service billing and questions about the treatment’s real-world effectiveness. AMCP strongly supports this legislation and urges Congress to pass the MVP Act to ensure Medicaid programs and their patients can access lifesaving therapies at an affordable cost. 

The House bill mirrors the Senate legislation (S.1637) and is identical to language introduced in the 118th Congress, apart from new implementation dates.

Click here to join AMCP in calling on Congress to support this legislation. 

Click here to learn more about the MVP Act. 

For media inquiries, contact AMCP.

About AMCP 
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models. Visit www.amcp.org